Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Stem Cells Dev. 2011 Aug;20(8):1371-81. doi: 10.1089/scd.2010.0456. Epub 2011 Jan 31.
Clinical and preclinical applications of human hematopoietic stem cells (HSCs) are often limited by scarcity of cells. Expanding human HSCs to increase their numbers while maintaining their stem cell properties has therefore become an important area of research. Here, we report a robust HSC coculture system wherein cord blood CD34(+) CD133(+) cells were cocultured with mesenchymal stem cells engineered to express angiopoietin-like-5 in a defined medium. After 11 days of culture, SCID repopulating cells were expanded ~60-fold by limiting dilution assay in NOD-scid Il2rg(-/-) (NSG) mice. The cultured CD34(+) CD133(+) cells had similar engraftment potential to uncultured CD34(+) CD133(+) cells in competitive repopulation assays and were capable of efficient secondary reconstitution. Further, the expanded cells supported a robust multilineage reconstitution of human blood cells in NSG recipient mice, including a more efficient T-cell reconstitution. These results demonstrate that the expanded CD34(+) CD133(+) cells maintain both short-term and long-term HSC activities. To our knowledge, this ~60-fold expansion of SCID repopulating cells is the best expansion of human HSCs reported to date. Further development of this coculture method for expanding human HSCs for clinical and preclinical applications is therefore warranted.
人造血干细胞(HSCs)的临床和临床前应用常常受到细胞数量的限制。因此,扩大人 HSCs 的数量,同时保持其干细胞特性,已成为一个重要的研究领域。在这里,我们报告了一种强大的 HSC 共培养系统,其中脐带血 CD34+CD133+细胞与表达血管生成素样蛋白 5 的间充质干细胞在定义的培养基中进行共培养。经过 11 天的培养,通过在 NOD-scid Il2rg(-/-)(NSG)小鼠中的有限稀释测定,SCID 重建造血细胞被扩增了60 倍。培养的 CD34+CD133+细胞在竞争性重建造血测定中与未培养的 CD34+CD133+细胞具有相似的植入潜力,并且能够有效地进行二次重建。此外,扩增的细胞在 NSG 受体小鼠中支持人类血细胞的强大多谱系重建,包括更有效的 T 细胞重建。这些结果表明,扩增的 CD34+CD133+细胞保持短期和长期 HSC 活性。据我们所知,这种 SCID 重建造血细胞的60 倍扩增是迄今为止报道的最佳人 HSCs 扩增。因此,有必要进一步开发这种共培养方法,以扩大人 HSCs 用于临床和临床前应用。